Le Lézard
Classified in: Health, Business
Subjects: SLS, MRR

Sunrise Group among the world's top ten chemical distributors


NEW YORK, May 22, 2023 /PRNewswire/ -- LEADING Chinese chemical distribution company Sunrise Group has secured a global ranking of tenth place and third place in the Asia-Pacific region on the latest ICIS Top 100 Chemical Companies list. According to its latest financial report, Ningbo-based Sunrise Group generated US$ 3.6 billion in sales.

In 2022, the company expanded into the pharmaceutical sector, acquiring Taizhou Dachen Pharmaceutical, a firm specializing in R&D and manufacturing of pharmaceutical raw materials and intermediates such as pyrazole and sitagliptin side chain. Taizhou Dachen Pharmaceutical generates an annual output of US$ 58 million. The deal has strengthened Sunrise Group's competitive advantage within the API and intermediate market. It has also paved the way for entry into the higher-end pharmaceutical preparation market.

Sunrise Group attributes its growth in sales to its ability to adapt to market changes quickly and optimize its product quality, service level, and supply chain management. This ability has enabled the company to increase its sales performance by 41% year-on-year in 2022, with a growth rate of 14% for customers and 10% on products.

The company has also modernized its warehouse and logistics center and launched a new brand image to reflect its growth within a changing market. Sunrise Group is committed to strengthening collaboration with its valued suppliers and customers worldwide and ensuring a unique contribution to the chemical distribution industry.

The company anticipates challenges in the export of China's chemical products in 2023 due to unfavorable geopolitical tensions, rising interest rates, and high inflation. However, Sunrise Group remains optimistic about the future market potential stimulated by the RCEP and economic growth in ASEAN and other regions. The company intends to leverage its expertise in chemical distribution and collaborate with its partners to advance technological innovation and market expansion in these fields. Despite the challenges of a highly competitive and dynamic industry, Sunrise Group has maintained its strength and continues to position itself at the forefront of industry innovation.

It looks forward to sustainable human health development. To learn more about Sunrise Group's services, interested parties can contact Sunrise Group to learn more about its services or email [email protected], or visit its website at www.sunrisechemical.com.

SOURCE Sunrise Group


These press releases may also interest you

at 22:30
Information Mediary Corp. and Adherence Partner to Launch Revolutionary Digital MMAS Integration for Medication Adherence
Information Mediary Corp (IMC) and Adherence have collaborated to introduce a digitized Morisky Medication Adherence Scale (MMAS), revolutionizing medication adherence management. This innovative solution signifies a significant advancement in...

at 22:15
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of a public offering of 804,999 shares...

at 20:20
PPMW Promotoras program awarded Montgomery Co. Underserved Communities Projects (UCP) grant to advance health outreach
Planned Parenthood of Metropolitan Washington, DC (PPMW) recently received an Underserved Communities Projects grant from Montgomery County, Maryland, to grow the PPMW Promotoras de Salud community health outreach program. The Promotoras de Salud...

at 20:06
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343?Anti-Claudin18.2 ADC?as Monotherapy for Advanced Gastric Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 20:00
Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today that China National Medical Products Administration (NMPA) has...

at 18:45
SHATTERPROOF AND ANTHEM BLUE CROSS AND BLUE SHIELD FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND A SUBSTANCE USE DISORDER
A substance use disorder (SUD) is a complex and often stigmatized health condition that affects countless individuals, families and communities. Stigma against people with a SUD extends beyond individual and interpersonal levels. The Shatterproof...

More news about Health...


News published on and distributed by: